Log in Subscribe

The glucagon-like peptides (GLP-1 and GLP-2) are proglucagon-derived peptides cosecreted from gut endocrine cells in response to nutrient ingestion

Cantu Sherman
· 3 min read
The glucagon-like peptides (GLP-1 and GLP-2) are proglucagon-derived peptides cosecreted from gut endocrine cells in response to nutrient ingestion

glp-1 inhibitors -1 acts as an incretin to lower blood glucose via stimulation of insulin secretion from islet beta cells. GLP-1 also exerts actions independent of insulin secretion, including inhibition of gastric emptying and acid secretion, reduction in food ingestion and glucagon secretion, and stimulation of beta-cell proliferation. Administration of GLP-1 lowers blood glucose and reduces food intake in human subjects with type 2 diabetes. GLP-2 promotes nutrient absorption via expansion of the mucosal epithelium by stimulation of crypt cell proliferation and inhibition of apoptosis in the small intestine. GLP-2 also reduces epithelial permeability, and decreases meal-stimulated gastric acid secretion and gastrointestinal motility.  glipizide used for  of GLP-2 in the setting of experimental intestinal injury is associated with reduced epithelial damage, decreased bacterial infection, and decreased mortality or gut injury in rodents with chemically induced enteritis, vascular-ischemia reperfusion injury, and dextran sulfate-induced colitis.

GLP-2 also attenuates chemotherapy-induced mucositis via inhibition of drug-induced apoptosis in the small and large bowel. GLP-2 improves intestinal adaptation and nutrient absorption in rats after major small bowel resection, and in humans with short bowel syndrome. The actions of GLP-2 are mediated by a distinct GLP-2 receptor expressed on subsets of enteric nerves and enteroendocrine cells in the stomach and small and large intestine. The beneficial actions of GLP-1 and GLP-2 in preclinical and clinical studies of diabetes and intestinal disease, respectively, has fostered interest in the potential therapeutic use of these gut peptides. Nevertheless, the actions of the glucagon-like peptides are limited in duration by enzymatic inactivation via cleavage at the N-terminal penultimate alanine by dipeptidyl peptidase IV (DP IV). Hence, inhibitors of DP IV activity, or DP IV-resistant glucagon-like peptide analogues, may be alternative therapeutic approaches for treatment of Current research of the RAS in diabetes mellitus.Staggered meal consumption facilitates appetite control without affecting Meal pattern may influence hormone and appetite dynamics and food intake.

The objective of the study was to determine the effects of staggered compared with nonstaggered meal consumption on hormone and appetite dynamics, food reward (i.e. "liking," "wanting"), and subsequent energy intake. The study was conducted in a randomized cross-over design. Participants (n = 38, age = 24 ± 6 4-course lunch (40% of the daily energy requirements) in 0 h (nonstaggered) or in 2 h with 3 within-meal pauses (staggered) followed by ad libitum food intake. Throughout the test sessions, glucagon-like peptide (GLP)-1, peptide tyrosine-tyrosine (PYY(3-36)), ghrelin, appetite, and food reward were measured. In the staggered compared with nonstaggered meal condition, peak values of GLP-1, PYY(3-36), and satiety were lower and time to peak values were higher (P < 02); the nadir value of hunger was higher, and time to nadir values of ghrelin and hunger were higher (P < 0001).

Prior to ad libitum food intake, GLP-1 concentrations and satiety ratings were greater, ghrelin concentrations and hunger ratings were smaller, and food "wanting" was less in the staggered compared with nonstaggered meal condition (P < 05). However, this did not affect ad libitum energy intake (1 ± 0 vs. 1 ± 0 MJ). In conclusion, staggered compared with nonstaggered meal consumption induces less pronounced hormone and appetite dynamics. Moreover, it results in higher final GLP-1 concentrations and satiety ratings, lower ghrelin concentrations and hunger ratings, and lower food "wanting" prior to ad libitum food intake. However, this was not translated into lower energy intake.Effects of exogenous glucagon-like peptide-1 on blood pressure, heart rate, gastric emptying, mesenteric blood flow and glycaemic responses to oral glucose in older individuals with normal glucose tolerance or type 2 diabetes.

North Terrace, Adelaide, SA, 5000, Australia.AIMS/HYPOTHESIS: A postprandial fall in BP occurs frequently in older individuals and in patients with type 2 diabetes. The magnitude of this decrease in BP is related to the rate of gastric emptying (GE). Intravenous administration of glucagon-like peptide-1 (GLP-1) attenuates the hypotensive response to intraduodenal glucose in healthy older individuals. We sought to determine the effects of exogenous GLP-1 on BP, GE, superior mesenteric artery (SMA) flow and glycaemic response to oral ingestion of glucose in healthy older individuals and patients with type 2 diabetes.METHODS: Fourteen older volunteers (six men, eight women; age 72 ± 1 years) and ten patients with type 2 diabetes (six men, four women; age 68 ± 3 years; HbA1c 6 ± 0% [48 ± 2 mmol/mol]; nine with blood glucose managed with metformin, two with a sulfonylurea and one with a dipeptidyl-peptidase 4 inhibitor) received an i.v.

infusion of GLP-1 (0 pmol kg(-1) min(-1)) or saline (154 mmol/l NaCl) for 150 min (t = -30 min to t = 120 min) in randomised order. At t = 0 min, volunteers consumed a radiolabelled 75 g glucose drink. BP was assessed with an automated device, GE by scintigraphy and SMA flow by ultrasonography.